F10 and thrombotic disease: Since their approval by the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) in 2010, direct-acting oral anticoagulants (DOACs) and in particular the factor Xa (FXa) inhibitors apixaban and rivaroxaban have been increasingly utilized to treat or prevent various thrombotic disease states [1–4].